A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 05 Apr 2018 Planned End Date changed from 28 Apr 2021 to 8 Dec 2021.
- 05 Apr 2018 Planned initiation date changed from 21 May 2018 to 7 May 2018.
- 19 Feb 2018 New trial record